Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by George Bondi on Jun 3rd, 2026

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) have received an average rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $25.00.

Several research firms have issued reports on PHAT. Stifel Nicolaus set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday, February 26th. Guggenheim lifted their price target on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Barclays raised shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $16.00 to $18.00 in a report on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Tuesday, April 21st.

Check Out Our Latest Report on Phathom Pharmaceuticals

Hedge Funds Weigh In On Phathom Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. purchased a new position in Phathom Pharmaceuticals in the fourth quarter worth $1,908,000. Hussman Strategic Advisors Inc. purchased a new position in Phathom Pharmaceuticals in the fourth quarter worth $2,439,000. GW&K Investment Management LLC grew its holdings in Phathom Pharmaceuticals by 9.1% in the third quarter. GW&K Investment Management LLC now owns 1,144,330 shares of the company’s stock worth $13,469,000 after purchasing an additional 95,858 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Phathom Pharmaceuticals in the third quarter worth $827,000. Finally, Stratos Wealth Partners LTD. purchased a new position in Phathom Pharmaceuticals in the fourth quarter worth $834,000. 99.01% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Stock Up 4.4%

Shares of PHAT stock opened at $9.65 on Wednesday. The firm has a market cap of $769.68 million, a price-to-earnings ratio of -4.55 and a beta of 0.50. The company’s 50 day moving average is $11.65 and its 200 day moving average is $13.16. Phathom Pharmaceuticals has a 52-week low of $4.47 and a 52-week high of $18.31.

Phathom Pharmaceuticals Company Profile

(Get Free Report)

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.